NEW YORK (AP) — Botox maker Allergan Plc. is buying Kythera Biopharmaceuticals for about $2.1 billion, adding a drug that destroys fat cells and eliminates the cosmetic condition referred to as ...
The rise of Botox has yet to see a plateau. And while the injection is most commonly associated with those in their mid 40s and 50s, millennials are finding new and interesting ways to maintain the no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results